PYGL and type 2 diabetes mellitus: PYGL inhibitors are already in development for treating type 2 diabetes and they are unlikely to be toxic to most cells because patients affected by Hers disease (an inherited glycogen storage disorder caused by deficiency of PYGL) [24].